CMCT Surges 43.9% on EPS Revision; ENHA, BFLY, CRDO, CAVA Follow
Stocks flagged by our EPS revision screener posted strong gains since detection. CMCT jumped 43.9% to $4.72 after EPS growth estimates hit 84.8%. ENHA gained 37.1% to $3.88 on a 140.4% EPS growth estimate. BFLY rose 24.3% to $5.68, CRDO climbed 23.4% to $264.76, and CAVA added 21.6% to $88.25 — all on upward estimate revisions and reinforcing catalysts.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| CMCT | Real Estate | 2026-06-04 | N/A | +43.9% |
| ENHA | Consumer Defensive | 2026-06-02 | N/A | +37.1% |
| BFLY | Healthcare | 2026-06-07 | N/A | +24.3% |
| CRDO | Technology | 2026-06-03 | N/A | +23.4% |
| CAVA | Consumer Cyclical | 2026-06-07 | N/A | +21.6% |
Why did CMCT stock jump in June 2026?
CMCT jumped 43.9% from $3.28 to $4.72 after its forward EPS growth estimate was revised to 84.8% on June 4.
The real estate stock lacked company-specific news, but the steep revision signaled a dramatic turn in earnings expectations, attracting buyers. The screener's early detection captured the move before the broader market fully priced in the upgrade.
CMCT EPS revision history → · Screener snapshot from 2026-06-04 →
FAQ: CMCT
Why did CMCT stock jump in June 2026?
CMCT rallied 43.9% after analysts raised its forward EPS growth estimate to 84.8% on June 4, driving demand from investors seeking undervalued real estate plays with improving earnings.
Is CMCT a buy after the rally?
The 84.8% EPS growth estimate implies strong earnings recovery, but the stock has already gained 43.9% since detection; investors should weigh sustainability of the revision against current valuation.
What is CMCT's EPS growth estimate?
CMCT's forward EPS growth estimate is 84.8%, reflecting expected earnings improvement next year.
Why did ENHA stock jump in June 2026?
ENHA jumped 37.1% from $2.83 to $3.88 after its forward EPS growth estimate was revised to 140.4% on June 2.
As a consumer defensive stock, the massive revision likely reflected a turnaround in earnings that the market had not anticipated. No news emerged in the window, making the estimate revision the clear catalyst.
ENHA EPS revision history → · Screener snapshot from 2026-06-02 →
FAQ: ENHA
Why did ENHA stock surge in June 2026?
ENHA surged 37.1% after its forward EPS growth estimate was raised to 140.4% on June 2, indicating a major expected earnings rebound in the consumer defensive sector.
What caused ENHA's price increase?
The price increase was caused by an upward revision in ENHA's EPS growth estimate to 140.4%, suggesting sharply higher future earnings, with no other news to explain the move.
Is ENHA's EPS growth estimate reliable?
A 140.4% EPS growth estimate is exceptionally high; investors should confirm the basis for the revision and monitor upcoming earnings reports for validation.
Why did BFLY stock jump in June 2026?
BFLY jumped 24.3% from $4.57 to $5.68 after its forward EPS growth estimate was revised to 26.8% on June 7.
The healthcare stock's improvement in earnings outlook, alongside growing adoption of its ultrasound technology, helped drive the rally. No additional news was reported, but the steady EPS upgrade supported sustained buying.
BFLY EPS revision history → · Screener snapshot from 2026-06-07 →
FAQ: BFLY
Why did BFLY stock jump in June 2026?
BFLY gained 24.3% after analysts raised its forward EPS growth estimate to 26.8% on June 7, signaling improved profitability prospects for the medical device company.
Is BFLY a buy after the rally?
The 26.8% EPS growth estimate supports a bullish outlook, but the stock has already risen 24.3% since detection; consider the company's revenue trajectory and market share before buying.
What is BFLY's EPS growth estimate?
BFLY's forward EPS growth estimate is 26.8%, reflecting expected earnings expansion in the coming year.
Why did CRDO stock jump in June 2026?
CRDO jumped 23.4% from $214.60 to $264.76 after analysts raised its forward EPS growth estimate to 41.3% on June 3, with a blowout Q4 earnings report as a catalyst.
Revenue surged 157% year-over-year to $437 million and non-GAAP EPS of $1.16 beat estimates by $0.14. Despite initial post-earnings volatility, analysts like Roth Capital and Jefferies raised price targets, reinforcing the upward revision and pushing the stock higher.
CRDO EPS revision history → · Screener snapshot from 2026-06-03 →
FAQ: CRDO
Why did CRDO stock jump in June 2026?
CRDO rose 23.4% after its EPS growth estimate was revised to 41.3% on June 3, fueled by a Q4 earnings beat with 157% revenue growth and AI-driven demand for its high-speed connectivity products.
What caused CRDO's surge?
The surge was caused by the combination of an upward EPS revision and strong earnings: Q4 revenue of $437 million beat expectations, and analysts responded with price target increases to $270 and $300.
Is CRDO a buy after the rally?
With a 41.3% EPS growth estimate and analyst price targets above $270, CRDO offers upside potential, but the stock has already rallied 125% in three months; new buyers should watch for pullbacks.
Why did CAVA stock jump in June 2026?
CAVA jumped 21.6% from $72.60 to $88.25 after its forward EPS growth estimate was revised to 35.7% on June 7, backed by a June 10 UBS upgrade to Buy with a $90 target.
UBS cited strong same-store sales, accelerating unit growth, and an attractive risk/reward after the stock's pullback. The upgrade reinforced the earnings revision, attracting both fundamental and momentum buyers.
CAVA EPS revision history → · Screener snapshot from 2026-06-07 →
FAQ: CAVA
Why did CAVA stock jump in June 2026?
CAVA gained 21.6% after its EPS growth estimate was raised to 35.7% on June 7, followed by a UBS upgrade to Buy on June 10 with a $90 price target, citing strong same-store sales and unit growth.
What caused CAVA's surge?
The surge was driven by the upward EPS estimate revision and reinforced by UBS's upgrade, which highlighted industry-leading unit growth and a rebound from the stock's April highs.
Is CAVA a buy after the rally?
With a 35.7% EPS growth estimate and analyst support at $90, CAVA looks attractive, but the stock has already rebounded 30% in 2026; consider entry after potential retracements.
Today's performers highlight that upward EPS estimate revisions remain a powerful leading indicator for price gains, especially when paired with sector trends or analyst upgrades. The concentration in healthcare, tech, and consumer cyclicals suggests broad earnings optimism across defensive and growth segments.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →